PMID- 19826974
OWN - NLM
STAT- MEDLINE
DCOM- 20091217
LR  - 20220310
IS  - 1098-8971 (Electronic)
IS  - 0272-8087 (Linking)
VI  - 29
IP  - 4
DP  - 2009 Nov
TI  - Genetic association studies in drug-induced liver injury.
PG  - 400-11
LID - 10.1055/s-0029-1240009 [doi]
AB  - Genetic studies on drug-induced liver injury (DILI) have proved challenging, both 
      because of their rarity and their difficulty in replicating observed effects. 
      However, significant progress has now been achieved by both candidate-gene and 
      genome-wide association studies. These two approaches are considered in detail, 
      together with examples of DILI due to specific drugs where consistent 
      associations have been reported. Particular consideration is given to 
      associations between antituberculosis drug-related liver injury and the "slow 
      acetylator" genotype for N-acetyltransferase 2, amoxicillin/clavulanate-related 
      liver injury, and the human leukocyte antigen (HLA) class II DRB1*1501 allele and 
      flucloxacillin-related injury and the HLA class I B*5701 allele. Although these 
      associations are drug-specific, the possibility that additional, more general 
      susceptibility genes for DILI exist requires further investigation, ideally by 
      genome-wide association studies involving international collaboration. The 
      possibility of interethnic variation in susceptibility to DILI also requires 
      further study.
FAU - Daly, Ann K
AU  - Daly AK
AD  - Institute of Cellular Medicine, Newcastle University Medical School, Newcastle 
      upon Tyne, United Kingdom.
FAU - Day, Chris P
AU  - Day CP
LA  - eng
GR  - Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20091013
PL  - United States
TA  - Semin Liver Dis
JT  - Seminars in liver disease
JID - 8110297
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antitubercular Agents)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*57:01 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*15:01 antigen)
RN  - 144O8QL0L1 (Diclofenac)
RN  - 43B2M34G2V (Floxacillin)
RN  - 74469-00-4 (Amoxicillin-Potassium Clavulanate Combination)
RN  - EC 2.3.1.5 (Arylamine N-Acetyltransferase)
RN  - EC 2.3.1.5 (NAT2 protein, human)
SB  - IM
MH  - Adverse Drug Reaction Reporting Systems
MH  - Amoxicillin-Potassium Clavulanate Combination/adverse effects
MH  - Anti-Bacterial Agents/adverse effects
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
MH  - Antitubercular Agents/adverse effects
MH  - Arylamine N-Acetyltransferase/genetics
MH  - Chemical and Drug Induced Liver Injury/enzymology/*genetics/immunology
MH  - Diclofenac/adverse effects
MH  - Floxacillin/adverse effects
MH  - *Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - HLA-B Antigens/genetics
MH  - HLA-DR Antigens/genetics
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Phenotype
MH  - *Polymorphism, Single Nucleotide
MH  - Risk Assessment
MH  - Risk Factors
RF  - 77
EDAT- 2009/10/15 06:00
MHDA- 2009/12/18 06:00
CRDT- 2009/10/15 06:00
PHST- 2009/10/15 06:00 [entrez]
PHST- 2009/10/15 06:00 [pubmed]
PHST- 2009/12/18 06:00 [medline]
AID - 10.1055/s-0029-1240009 [doi]
PST - ppublish
SO  - Semin Liver Dis. 2009 Nov;29(4):400-11. doi: 10.1055/s-0029-1240009. Epub 2009 
      Oct 13.